Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Biological Procedures Online

Engineering SIM-1 and MZ-1 PROTACs for enhanced target degradation in KSHV-infected immortalized endothelial cells

  1. 1Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205 USA
  2. 2Department of Pharmacology, The Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 USA

Abstract

Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s Sarcoma (KS), which are still lacking of treatment options. Members of the bromodomain and extra-terminal domain (BET) family, especially bromodomain-containing protein 4 (BRD4), play important roles in RNA polymerase II–mediated transcriptional regulation and are required for the expression of many tumor-driving oncogenes in various cancer cells. Therefore, BET proteins have become attractive targets for anticancer drug development. Our recent studies showed that KSHV-infected immortalized endothelial cells displayed strong resistance to BET inhibitors such as (+)-JQ1. In contrast, we found out MZ-1 and SIM-1, two of BRD4 PROTAC degraders, as effective inhibitors of cell growth in these cells. To develop PROTAC molecules with enhanced BRD4 degradation potency, we introduced an (S)-methyl group at the benzylic position of the VHL ligand in the VHL-based BRD4 PROTACs MZ-1 and SIM-1, thereby designing and generating MZ-1-ME and SIM-1-ME, respectively. In KS cellular model, MZ-1-ME and SIM-1-ME exhibited enhanced BRD4 degradation and anticancer activities compared with their parental compounds, which may represent promising PROTACs for development of BRD4-targeted therapies against KS.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12575-026-00360-2.

Related

  1. Ubiquitin ligase CHFR impairs Tie2 signaling via K48-linked ubiquitylation and degradation of Akt1 in endothelial cells
    Mohammad Owais Ansari, Gary C.H. Mo, Lasanthi Jayathilaka +3
    Journal of Biological ChemistryPeer-reviewedLicence not statedMolecular biology & gene regulationCrossref
  2. Biofilm Engineering for Efficient Substrate‐Enzyme Interactions to Enhance Enzymatic PET Degradation
    Xinyu Zhou, Xinyu Zhou, Lilin Feng +6
    Microbial BiotechnologyPeer-reviewedCC BY-NC 4.0Full textMolecular biology & gene regulationPMC
  3. ER Stress Induces Endothelial Dysfunction Linked to Mitochondrial Redox Imbalance and Enhanced Mitochondrial Bioenergetics in Penile Erectile Tissue
    Alfonso Gómez del Val, Cristina Contreras, Lucía Olmos +8
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  4. Model-Guided Engineering of NS1-Truncated Influenza OP7 Particles with Enhanced Interferon-Mediated Antiviral Activity
    J. Piasecka, D. Ruediger, U. Reichl +1
    bioRxivPreprintCC BY-NCFull textMolecular biology & gene regulationbioRxiv
  5. Discovery of Putative Phosphorylation Sites in Cre1 and Ace1 as Engineering Targets for Enhanced Cellulase Production in Trichoderma reesei
    Jiahui Liu, Sunxing Wang, Xin Gao +2
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMC
BibTeX
@article{chen2026engineering,
  title = {{Engineering SIM-1 and MZ-1 PROTACs for enhanced target degradation in KSHV-infected immortalized endothelial cells}},
  author = {Jungang Chen and Zhengyu Wang and Jarna Karmoker and Jiaojiao Fan and Hongfei Zhou and Lu Dai and Hong-Yu Li and Zhiqiang Qin},
  journal = {Biological Procedures Online},
  year = {2026},
  month = aug,
  doi = {10.1186/s12575-026-00360-2},
  url = {https://doi.org/10.1186/s12575-026-00360-2},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Engineering SIM-1 and MZ-1 PROTACs for enhanced target degradation in KSHV-infected immortalized endothelial cells
AU  - Jungang Chen
AU  - Zhengyu Wang
AU  - Jarna Karmoker
AU  - Jiaojiao Fan
AU  - Hongfei Zhou
AU  - Lu Dai
AU  - Hong-Yu Li
AU  - Zhiqiang Qin
PY  - 2026
DA  - 2026/08/14
JO  - Biological Procedures Online
DO  - 10.1186/s12575-026-00360-2
UR  - https://doi.org/10.1186/s12575-026-00360-2
AB  - Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s Sarcoma (KS), which are still lacking of treatment options. Members of the bromodomain and extra-terminal domain (BET) family, especially bromodomain-containing protein 4 (BRD4), play important roles in RNA polymerase II–mediated transcriptional regulation and are required for the expression of many tumor-driving oncogenes in various cancer cells. Therefore, BET proteins have become attractive targets for anticancer drug development. Our recent studies showed that KSHV-infected immortalized endothelial cells displayed strong resistance to BET inhibitors such as (+)-JQ1. In contrast, we found out MZ-1 and SIM-1, two of BRD4 PROTAC degraders, as effective inhibitors of cell growth in these cells. To develop PROTAC molecules with enhanced BRD4 degradation potency, we introduced an (S)-methyl group at the benzylic position of the VHL ligand in the VHL-based BRD4 PROTACs MZ-1 and SIM-1, thereby designing and generating MZ-1-ME and SIM-1-ME, respectively. In KS cellular model, MZ-1-ME and SIM-1-ME exhibited enhanced BRD4 degradation and anticancer activities compared with their parental compounds, which may represent promising PROTACs for development of BRD4-targeted therapies against KS.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12575-026-00360-2.
SN  - 1480-9222
ER  -